Akili, Inc.: Nasdaq/NYSE listing notice — Akili receives 180-day Nasdaq extension to Oct 21, 2024; shareholders approve reverse stock split

October 21, 2024 (the “Extension Notice”), to regain compliance with Nasdaq’s minimum closing bid price rule required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). Nasdaq’s determination follows the Company’s recent request for such additional compliance period and is based, in part, on the Company’s written notice to the Nasdaq Staff of its intention to cure the deficiency during the additional compliance period and if necessary, by effecting a reverse stock split. Previously, on October 24, 2023, the Company received a written notifica

Proposal 2 – Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 The Company’s stockholders approved Proposal 2. The votes were cast as follows: For Against Abstain Broker Non-Votes 65,287,853 127,909 31,431 0

Proposal 1 – Election of Class II Directors to the Board The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation, death or removal. The votes were cast as follows: Nominee For Withhold Broker Non-Votes William “BJ” Jones, Jr. 56,884,764 489,310 8,073,119 Christine Lemke 56,962,983 411,091 8,073,119

Proposal 3 – Approval of an Amendment to the Company’s Certificate of Incorporation to Give the Board Discretionary Authority to Effect a Reverse Stock Split The Company’s stockholders approved Proposal 3. The votes were cast as follows: For Against Abstain Broker Non-Votes 64,553,169 675,020 219,004 0